Enalaprilat Inhibits Zinc-Dependent Oligomerization of Metal-Binding Domain of Amyloid-beta Isoforms and Protects Human Neuroblastoma Cells from Toxic Action of these Isoforms
Intact amyloid-β peptides (Aβ) may undergo prion-like aggregation when they interact with chemically or structurally modified variants of Aβ present in extracellular pathohistological inclusions (amyloid plaques). This aggregation is regarded as one of the key molecular mechanisms of Alzheimer’s disease (AD) pathogenesis. Zinc ions are involved in the pathological dimerization and oligomerization of natural Aβ isoforms, and zinc-induced oligomers can also initiate the pathological aggregation of Aβ. Based on the earlier found molecular mechanism of zinc-dependent oligomerization of Aβ, it has been suggested that the targeted inhibition of the 11EVHH14 site in one Aβ molecule from zinc-mediated interactions with the same site of another Aβ molecule can effectively inhibit the oligomerization and aggregation of Aβ. Taking into account the similarity in the structural organization of zinc-binding sites within Aβ and angiotensin-converting enzyme (ACE), we hypothesized that inhibitors of the ACE active sites could specifically interact with the 11EVHH14 site of Aβ. Using a surface plasmon resonance biosensor and nuclear magnetic resonance spectroscopy, we have found that the ACE inhibitor enalaprilat effectively inhibits zinc-dependent dimerization of the metal-binding domains of intact Aβ and Aβ with isomerized Asp7 (isoAβ). We have also found that enalaprilat protects SH-SY5Y human neuroblastoma cells from the toxic effects of Aβ(1–42) and isoAβ(1–42), which are among the most common components of amyloid plaques. The results confirm the role of zincdependent oligomerization of Aβ in AD pathogenesis and make it possible one to consider enalaprilat as a prototype of antiaggregation agents for treating AD.
KeywordsAlzheimer’s disease amyloid-beta isoaspartate enalaprilat zinc NMR spectroscopy surface plasmon resonance neuroblastoma SH-SY5Y
Unable to display preview. Download preview PDF.
- 5.Bachurin S.O., Gavrilova S.I., Samsonova A., Barreto G.E., Aliev G. 2017. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol. Res. pii: S1043-6618(17)30937-4. doi 10.1016/ j.phrs.2017.11.021Google Scholar
- 6.Cummings J., Lee G., Mortsdorf T., Ritter A., Zhong K. 2017. Alzheimer’s disease drug-development pipeline: 2017. Alzheimers Dement. 3 (3), 367–384.Google Scholar
- 20.Mezentsev Y.V., Medvedev A.E., Kechko O.I., Makarov A.A., Ivanov A.S., Mantsyzov A.B., Kozin S.A. 2016. Zinc-induced heterodimer formation between metal-binding domains of intact and naturally modified amyloid-beta species: Implication to amyloid seeding in Alzheimer’s disease? J. Biomol. Struct. Dyn. 34, 2317–2326.CrossRefPubMedGoogle Scholar
- 25.Tzakos A.G., Galanis A.S., Spyroulias G.A., Cordopatis P., Manessi–Zoupa E., Gerothanassis I.P. 2003. Structure–function discrimination of the N- and Ccatalytic domains of human angiotensin-converting enzyme: Implications for Cl–activation and peptide hydrolysis mechanisms. Protein Eng. 16, 993–1003.CrossRefPubMedGoogle Scholar
- 29.Polshakov V.I., Mantsyzov A.B., Kozin S.A., Adzhubei A.A., Zhokhov S.S., van Beek W., Kulikova A.A., Indeykina M.I., Mitkevich V.A., Makarov A.A. 2017. A binuclear zinc interaction fold discovered in the homodimer of Alzheimer’s amyloid-beta fragment with taiwanese mutation D7H. Angew. Chem. Int. Ed. Engl. 56, 11734–11739.CrossRefPubMedGoogle Scholar
- 30.Mitkevich V.A., Petrushanko I.Y., Yegorov Y.E., Simonenko O.V., Vishnyakova K.S., Kulikova A.A., Tsvetkov P.O., Makarov A.A., Kozin S.A. 2013. Isomerization of Asp7 leads to increased toxic effect of amyloid–β42 on human neuronal cells. Cell Death Disease. 4, e939.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Mitkevich V., Kulikova A.A., Barykin E., Petrushanko I., Yurinskaya M., Vinokurov M., Evgen’ev M., Kozin S.A., Makarov A.A. 2015. HSP70 protects neuronal cells from toxic effect of amyloid beta and its isoforms. FEBS J. 282, 176–176.Google Scholar
- 41.Toropygin I.Y., Kugaevskaya E.V., Mirgorodskaya O.A., Elisseeva Y.E., Kozmin Y.P., Popov I.A., Nikolaev E.N., Makarov A.A., Kozin S.A. 2008. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg5–His6 bond of Alzheimer’s Aβ-(1–16) peptide and its isoAsp7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 22, 231–239.CrossRefPubMedGoogle Scholar
- 42.Nisbet R.M., Nuttall S.D., Robert R., Caine J.M., Dolezal O., Hattarki M., Pearce L.A., Davydova N., Masters C.L., Varghese J.N., Streltsov V.A. 2013. Structural studies of the tethered N-terminus of the Alzheimer’s disease amyloid-β peptide. Proteins: Struct. Funct., Bioinf. 81, 1748–1758.CrossRefGoogle Scholar
- 43.Dong Y.F., Kataoka K., Tokutomi Y., Nako H., Nakamura T., Toyama K., Sueta D., Koibuchi N., Yamamoto E., Ogawa H., Kim-Mitsuyama S. 2011. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J. 25, 2911–2920.CrossRefPubMedGoogle Scholar